Sinphar Pharmaceutical Co.,Ltd. (TPE:1734)

Market Cap	6.00B
Revenue (ttm)	3.18B
Net Income (ttm)	306.71M
Shares Out	181.14M
EPS (ttm)	1.69
PE Ratio	19.58
Forward PE	17.70
Dividend	1.00 (3.02%)
Ex-Dividend Date	Sep 4, 2024

Volume	179,915
Average Volume	289,311
Open	33.10
Previous Close	33.10
Day's Range	32.55 - 33.10
52-Week Range	27.25 - 36.30
Beta	0.28
RSI	52.30
Earnings Date	May 14, 2025

About Sinphar Pharmaceutical

Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and oth...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1977
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1734

Financial Performance

In 2024, Sinphar Pharmaceutical's revenue was 3.15 billion, an increase of 6.33% compared to the previous year's 2.96 billion. Earnings were 304.71 million, a decrease of -18.78%.